百济 JPM 2025.pdf

1、143RD ANNUAL J.P.MORGAN HEALTHCARE CONFERENCE 2025January 13-16,2025|San Francisco,CaliforniaAn Inflection Point 2Certain statements contained in this presentation and in the accompanying oral presentation,other than statements of fact that are independently verifiable at the date hereof,constitute

2、forward looking statements.Examples of such forward-looking statements include statements regarding the projected size of the oncology market and related sectors;BeiGenes research,discovery,pre-clinical and early-stage clinical programs and plans including proof of concept timing;the advancement of

3、and anticipated clinical development and the conduct of late-stage clinical trials;expected data readouts and approvals;additional planned commercial product launches including tablet formulations;projected regulatory milestones and commercialization of BeiGenes medicines;the ability of BeiGenes ass

4、ets to meaningfully outperform current medicines and address all lines of therapy;the potential for BeiGene to have a significant market share in hematologic diseases;the projected peak revenue potential for BeiGenes assets;BeiGenes ability to successfully redomicile to Switzerland;the ability for B

5、eiGene to become the most impactful global oncology company;and BeiGenes future revenue,profitability and growth.Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors,including BeiGenes ability to demonstrate the efficacy

6、 and safety of its drug candidates;the clinical results for its drug candidates,which may not support further development or marketing approval;actions of regulatory agencies,which may affect the initiation,timing and progress of clinical trials and marketing approval;BeiGenes ability to achieve com